US 7,892,538 B2Granted

Monovalent ligand of the FcαRI receptor as an anti-inflammatory agent

AssigneeInstitut National de la Sante et de la Recherche

InventorsRenato Monteiro, Benoît Pasquier, Ulrich Blank, Marc Benhamou, Pierre Launay, Marina Pretolani

Life of this patent

Estimating the term…

Abstract

The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the FcαRI receptor for the treatment of inflammatory diseases.

Claims14

Dependent claims

A method of treating an inflammatory disease in a mammal, which comprises administering to the mammal an anti-inflammatory agent consisting of a monovalent antigen-binding fragment of an antibody directed against the EC2 domain of the FcαRI receptor.

Dependencies are inferred from the claim text.

Facts

Application: 10/591,642Filed 4 Mar 2005
Priority: EP 042906155 Mar 2004
Published: US 2008/0085280 A110 Apr 2008
Granted: 22 Feb 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07K 16/283
Against the immunoglobulin superfamily: against Fc-receptors, e.g. CD16, CD32, CD64
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 7/12
Drugs for disorders of the blood or the extracellular fluid: antidiuretics, e.g. drugs for diabetes insipidus

Family

US 2008/0085280 A1Pre-grant publication · published 10 Apr 2008
US 7,892,538 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results